FY2018 Earnings Estimate for Nevro Corp Issued By Leerink Swann (NVRO)

Nevro Corp (NYSE:NVRO) – Equities researchers at Leerink Swann lowered their FY2018 EPS estimates for Nevro in a report issued on Tuesday, November 6th. Leerink Swann analyst D. Antalffy now expects that the medical equipment provider will post earnings of ($1.34) per share for the year, down from their prior estimate of ($1.10). Leerink Swann currently has a “Outperform” rating and a $90.00 price objective on the stock. Leerink Swann also issued estimates for Nevro’s Q3 2019 earnings at ($0.17) EPS, FY2019 earnings at $0.01 EPS, Q1 2020 earnings at $0.13 EPS, Q2 2020 earnings at $0.18 EPS, Q3 2020 earnings at ($0.05) EPS and FY2020 earnings at $0.48 EPS.

Nevro (NYSE:NVRO) last released its quarterly earnings data on Monday, November 5th. The medical equipment provider reported ($0.37) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.07). Nevro had a negative net margin of 11.64% and a negative return on equity of 17.89%. The business had revenue of $95.60 million for the quarter, compared to the consensus estimate of $94.29 million. During the same quarter last year, the business earned ($0.21) EPS. Nevro’s revenue for the quarter was up 16.2% compared to the same quarter last year.

Several other equities analysts have also commented on the stock. Goldman Sachs Group lowered shares of Nevro from a “neutral” rating to a “sell” rating and lowered their price objective for the company from $60.00 to $44.00 in a research report on Friday, October 19th. Zacks Investment Research lowered shares of Nevro from a “hold” rating to a “sell” rating in a research report on Thursday, September 6th. BMO Capital Markets lowered their price objective on shares of Nevro from $80.00 to $76.00 and set an “outperform” rating for the company in a research report on Monday, August 6th. Morgan Stanley lowered their price objective on shares of Nevro from $88.00 to $65.00 and set an “equal weight” rating for the company in a research report on Tuesday, July 17th. Finally, Bank of America lowered their price objective on shares of Nevro from $102.00 to $77.00 and set a “buy” rating for the company in a research report on Tuesday, July 17th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the company’s stock. Nevro presently has an average rating of “Hold” and an average price target of $64.11.

NVRO stock opened at $43.05 on Thursday. Nevro has a 52 week low of $35.41 and a 52 week high of $94.34. The company has a debt-to-equity ratio of 0.62, a current ratio of 8.05 and a quick ratio of 6.29. The firm has a market cap of $1.15 billion, a price-to-earnings ratio of -34.44 and a beta of -0.29.

Several institutional investors have recently added to or reduced their stakes in the company. Xact Kapitalforvaltning AB lifted its holdings in shares of Nevro by 23.1% in the 2nd quarter. Xact Kapitalforvaltning AB now owns 4,258 shares of the medical equipment provider’s stock worth $340,000 after acquiring an additional 800 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of Nevro by 3.1% in the 2nd quarter. Rhumbline Advisers now owns 28,525 shares of the medical equipment provider’s stock worth $2,278,000 after acquiring an additional 856 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. lifted its holdings in shares of Nevro by 69.7% in the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,432 shares of the medical equipment provider’s stock worth $210,000 after acquiring an additional 999 shares during the last quarter. UBS Group AG lifted its holdings in shares of Nevro by 38.0% in the 1st quarter. UBS Group AG now owns 5,479 shares of the medical equipment provider’s stock worth $474,000 after acquiring an additional 1,509 shares during the last quarter. Finally, Gradient Investments LLC lifted its holdings in shares of Nevro by 38.5% in the 2nd quarter. Gradient Investments LLC now owns 9,195 shares of the medical equipment provider’s stock worth $734,000 after acquiring an additional 2,555 shares during the last quarter.

Nevro Company Profile

Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Further Reading: How Do Tariffs Affect Trade Balances?

Earnings History and Estimates for Nevro (NYSE:NVRO)

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply